In particular, oxidized PcActx peptide clearly inhibited the mRNA expression levels of calb1, calb2, gabra1, grm1, gria1b, grin2b gat1, slc1a2b, gad1b, and glsa. Thus, PcActx peptide represents a promising therapeutic candidate for epilepsy management, the mechanism of action of which may involve regulation of calcium and GABAergic-glutamatergic signal pathways (Figure 11). This evidence concerns the gene SLC6A1 and epilepsy.